Supplementary Figure S5 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma

Ilango Balakrishnan; Krishna Madhavan; Angela Pierce; Joshua Michlin; Breauna Brunt; Senthilnath Lakshmanachetty; Dong Wang; John DeSisto; Zachary James Nuss; Nathan Davidson; Faye Walker; Ammu Suresh; Andrew M. Donson; Bridget Sanford; Kenneth L. Jones; Etienne Danis; Siddhartha S. Mitra; Adam L. Green; Nathan Dahl; Rajeev Vibhakar; Sujatha Venkataraman

doi:10.1158/0008-5472.29918858

Key Points

Improved binding of the best CD99 antibody clone was observed, enhancing targeting for diffuse midline glioma.
The affinity of 10D1 antibody was assessed using western blotting across various cell types including DMG and normal human astrocytes.
This assessment employed functional effects on normal human astrocytes and induced pluripotent stem cells to evaluate therapeutic efficacy.
Findings highlight the potential of anti-CD99 antibodies as a targeted approach in treating diffuse midline glioma, advocating for further research.

Implication

Functional analysis shows improved binding of CD99 antibody clones in diffuse midline glioma, suggesting therapeutic potential.

Abstract

Selection and affinity of best binding CD99 antibody clones using western blotting and functional effects of 10D1 in DMG, normal human astrocytes, and iPScs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Balakrishnan et al. (2025) studied this question.

synapsesocial.com/papers/68af56faad7bf08b1eadd189 https://doi.org/10.1158/0008-5472.29918858

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S5 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S5 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers